Experiments on U-937 cells show that CX3CR1 expression increases when CXCR4 activity is blocked by an inhibitor, suggesting a potential side effect of CXCR4-targeting drugs, where AML cells might migrate to the CNS after release from the bone marrow [125]. The gene discussed is CX3CR1; the disease is acute myeloid leukemia.